© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
Cardiovascular Disease
FDA Fast Tracks Empagliflozin to Improve Outcomes Following Heart Attack
September 18, 2020
Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.
Study: Use of Azithromycin With QT Prolonging Drugs Linked to Cardiac Events
September 18, 2020
A study compared cardiac events associated with azithromycin versus amoxicillin.
Study: Gut Microbiome Data May Be Useful in Screening for Heart Disease
September 10, 2020
The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.
FDA Approves New Doses of Dulaglutide for the Treatment of Type 2 Diabetes
September 08, 2020
Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.
Study: No Link Between Antihypertensive Medications and Cancer Risk
September 03, 2020
There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.
Dapagliflozin Reduces Risk of Kidney Failure, Death in Chronic Kidney Disease
August 31, 2020
Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.
Empagliflozin Reduces Heart Failure Hospitalization, Death Risk in Phase 3 Trial
July 31, 2020
Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.
Study Suggests Azithromycin Associated With Heart Death Risk
July 13, 2020
Azithromycin may be linked to a greater risk of cardiovascular death, according to a recent study.
Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease
July 03, 2020
A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.
Risk of Death By Heart Failure Increases With Recent Diagnosis of Type 2 Diabetes
July 02, 2020
Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.
FDA OKs Ticagrelor Indication to Reduce Risk of First Heart Attack, Stroke in Patients With High-Risk CAD
June 01, 2020
This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.
Analysis: Women, Older Adults Underrepresented in Cholesterol Drug Trials
May 25, 2020
Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.
Study: Heart Disease Risk Associated With Cognitive Decline
May 20, 2020
Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.
No Short-Term Cognitive Harm From Low LDL-C Levels Achieved With Evolocumab
May 15, 2020
A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.
NYU Study Finds High Blood Pressure Medications Use Safe with COVID-19
May 06, 2020
Results of the study showed that antihypertensive medications do not put individuals at increased risk for COVID-19.
FDA OKs Dapagliflozin for Heart Failure With Reduced Ejection Fraction
May 06, 2020
Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.
US Rural Communities Face Disparities in Heart Disease Outcomes
April 23, 2020
Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.
Bempedoic Acid Tablets Now Available in Pharmacies
April 01, 2020
Bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-statin low-density lipoprotein-cholesterol lowering medicine, is now available in US pharmacies.
Ticagrelor Monotherapy Shows Cardiovascular Benefit in Patients with Diabetes
March 31, 2020
Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.
Alirocumab Evaluated for Treatment of Homozygous Familial Hypercholesterolemia
March 31, 2020
Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.